Literature DB >> 1695829

Enzymes of androgen formation and degradation in the human prostate.

W Bartsch1, H Klein, U Schiemann, H W Bauer, K D Voigt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1695829     DOI： 10.1111/j.1749-6632.1990.tb34282.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  10 in total

Review 1.  Neurogenic pain and steroid synthesis in the spinal cord.

Authors:  Christine Patte-Mensah; Cherkaouia Kibaly; Domitille Boudard; Véronique Schaeffer; Aurélie Béglé; Simona Saredi; Laurence Meyer; Ayikoe G Mensah-Nyagan
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 2.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

Review 3.  Cholesterol as a potential target for castration-resistant prostate cancer.

Authors:  Alexis L Twiddy; Carlos G Leon; Kishor M Wasan
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

4.  Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Authors:  James L Mohler; Mark A Titus; Elizabeth M Wilson
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

5.  Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.

Authors:  Stephanie T Page; Daniel W Lin; Elahe A Mostaghel; Brett T Marck; Jonathan L Wright; Jennifer Wu; John K Amory; Peter S Nelson; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

Review 6.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

7.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

8.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

Review 9.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

Review 10.  The role of androgens in experimental rodent mammary carcinogenesis.

Authors:  Jaesung Choi; Basil Psarommatis; Yan Ru Gao; Yu Zheng; David J Handelsman; Ulla Simanainen
Journal:  Breast Cancer Res       Date:  2014-11-25       Impact factor: 6.466
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.